788 related articles for article (PubMed ID: 15516696)
1. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
[TBL] [Abstract][Full Text] [Related]
2. [Detail study of angiotensin-receptor blockade versus ACE-inhibition in type 2 diabetes with nephropathy].
Nitschmann S; Girndt M; Köhler H
Internist (Berl); 2005 Aug; 46(8):923-4, 926. PubMed ID: 15990988
[No Abstract] [Full Text] [Related]
3. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study.
Barnett AH
Acta Diabetol; 2005 Apr; 42 Suppl 1():S42-9. PubMed ID: 15868119
[TBL] [Abstract][Full Text] [Related]
4. Preventing renal complications in type 2 diabetes: results of the diabetics exposed to telmisartan and enalapril trial.
Barnett A
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S132-5. PubMed ID: 16565237
[TBL] [Abstract][Full Text] [Related]
5. Prevention of loss of renal function over time in patients with diabetic nephropathy.
Barnett A
Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
[TBL] [Abstract][Full Text] [Related]
6. [Diabetes and Nephropathy: ACE inhibitor for type 1, AT1 blocker for type 2].
Zidek W
MMW Fortschr Med; 2004 Oct; 146(42):51-2. PubMed ID: 15536706
[No Abstract] [Full Text] [Related]
7. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design of diabetics exposed to telmisartan and enalapril (DETAIL) study.
Rippin J; Bain SC; Barnett AH;
J Diabetes Complications; 2002; 16(3):195-200. PubMed ID: 12015188
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
Pathak JV; Dass EE
Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
[TBL] [Abstract][Full Text] [Related]
10. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
11. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
12. Effects of telmisartan and enalapril on renoprotection in patients with mild to moderate chronic kidney disease.
Nakamura T; Fujiwara N; Kawagoe Y; Sugaya T; Ueda Y; Koide H
Eur J Clin Invest; 2010 Sep; 40(9):790-6. PubMed ID: 20584070
[TBL] [Abstract][Full Text] [Related]
13. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.
Ravid M; Lang R; Rachmani R; Lishner M
Arch Intern Med; 1996 Feb; 156(3):286-9. PubMed ID: 8572838
[TBL] [Abstract][Full Text] [Related]
14. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
Luque Otero M; Martell Claros N;
Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
[TBL] [Abstract][Full Text] [Related]
15. ACE-I and ARBs in early diabetic nephropathy.
Mauer M; Zinman B; Gardiner R; Drummond KN; Suissa S; Donnelly SM; Strand TD; Kramer MS; Klein R; Sinaiko AR
J Renin Angiotensin Aldosterone Syst; 2002 Dec; 3(4):262-9. PubMed ID: 12584670
[TBL] [Abstract][Full Text] [Related]
16. [In the DETAIL. Kidney protection in manifestations of microalbuminuria].
MMW Fortschr Med; 2006 Jun; 148(26):51. PubMed ID: 16875382
[No Abstract] [Full Text] [Related]
17. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
[TBL] [Abstract][Full Text] [Related]
18. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
[TBL] [Abstract][Full Text] [Related]
19. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
Sengul AM; Altuntas Y; Kürklü A; Aydin L
Diabetes Res Clin Pract; 2006 Feb; 71(2):210-9. PubMed ID: 16112244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
